Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Cash & Equivalents (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Cash & Equivalents for 12 consecutive years, with $163.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 40.96% to $163.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $163.1 million, a 40.96% increase, with the full-year FY2025 number at $163.1 million, up 40.96% from a year prior.
  • Cash & Equivalents was $163.1 million for Q4 2025 at Iovance Biotherapeutics, up from $158.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $543.5 million in Q1 2023 to a low of $114.9 million in Q4 2023.
  • A 3-year average of $202.0 million and a median of $163.6 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 75.31% in 2024, then surged 40.96% in 2025.
  • Iovance Biotherapeutics' Cash & Equivalents stood at $114.9 million in 2023, then rose by 0.7% to $115.7 million in 2024, then soared by 40.96% to $163.1 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Cash & Equivalents are $163.1 million (Q4 2025), $158.1 million (Q3 2025), and $132.5 million (Q2 2025).